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Miscellaneous Rheumatic Diseases
73. IS THERE A DELAY IN SPECIALIST REFERRAL OF HOT
SWOLLEN JOINT?
Emma Mannan, Venkat Reddy, Christopher Pearce, James Peters,
Ian Giles and Mike Shipley
Rheumatology, University College Hospital, London, UK
Background: Patients with acute, hot, swollen joints commonly
present to general practitioners, emergency departments and/or
acute admitting teams rather than directly to rheumatology. It is
imperative to consider septic arthritis in the differential diagnosis of
these patients. The British Society of Rheumatology (BSR) has
produced guidelines for the management of this condition, which
include recommendations for early specialist referral and joint
aspiration of all patients with suspected septic arthritis. We examined
whether the initial management of patients with acute hot swollen
joint(s) at University College London Hospital (UCLH) follows BSR
guidelines.
Methods: For the period Feb to Nov 2009, appropriate patients were
identified by searching the UCLH database using the diagnostic terms,
‘‘pyogenic arthritis’’, ‘‘septic arthritis’’ and ‘‘gout’’; and from all joint
aspirate requests sent to microbiology. Medical notes were obtained
and any patients who had elective arthroscopies or chronic
(>6 weeks) symptoms were excluded. Data were collected on the
time taken from the onset of symptoms to specialist (orthopaedic/
rheumatology) referral and joint aspiration, collection of blood cultures
and antibiotic treatment with or without microbiology advice.
Results: Twenty patients were identified with hot swollen (18
monoarticular, 3 prosthetic) joint(s) of <2 weeks duration. Of whom,
3/20 (15%) were admitted directly to rheumatology, 7/20 (35%) to the
acute admissions unit, 3/20 (15%) to orthopaedic, 4/20 (20%) to a
medical team and 1/20 (5%) to general surgery. In 19 (95%) cases,
specialist (rheumatology/orthopaedic) advice was sought. Of 14 cases
not seen directly by specialists 9 (64%) were referred at 24–48 h and
5 (36%) at 48–192 h. All 20 patients had joint aspiration. In 9/20 (45%)
of cases, joint aspiration was performed in less than 6 h, 3/20 (15%)
cases at 6-24h and 6/20 (30%) cases at 24–192 h and was not
recorded in two patients. Of these, crystals were identified in two and
one was culture positive. Blood cultures were received for only 6/20
(30%) of cases and only clearly documented to have been taken prior
to antibiotic therapy and none were positive. Of 14/20 (70%) started on
antibiotic treatment empirically, only 6 (42%) were preceded by joint
aspiration. In the 6 patients not treated with antibiotics due to low
index of suspicion of septic arthritis, synovial fluid and blood cultures
were negative. Microbiology advice was sought in 10/20 (50%) of
cases by the admitting teams but the timing of this advice is unclear.
Conclusions: Despite the provision of 24 h rheumatology and
orthopaedic cover at UCLH, we found a significant delay in acute
medical firms seeking specialist advice on the management of patients
with acute, hot swollen joints with subsequent deviation from BSR
guidelines. Consequently, we plan to increase awareness of these
guidelines amongst medical firms at UCLH.
Disclosure statement: All authors have declared no conflicts of
interest.
74. A PROSPECTIVE AUDIT OF THE DIAGNOSIS AND
MANAGEMENT OF HOT SWOLLEN JOINTS IN ADULTS AT A
DISTRICT GENERAL HOSPITAL
Anupam Paul and Shirley Rigby
Rheumatology, Warwick Hospital, Warwick, UK
Background: Hot swollen joint is a common presentation and has a
wide differential diagnosis of which the most serious is septic arthritis
(SA), with a significant mortality and morbidity in case of inappropriate
management. Yet this treatable medical emergency is often treated
sub-optimally leading to adverse consequences. This audit has been
undertaken to assess our practice against the joint BSR and BHPR,
BOA, RCGP and BSAC guidelines published in 2006.
Methods: Data have been collected prospectively for all patients
either admitted with less than 2 weeks history of hot swollen joint or
developing this condition as an inpatient over 1-year period. Audit
standards suggested in the guideline has been the prime focus of this
audit.
Results: A total of 32 patients presenting with hot swollen joints have
been audited. Out of these, 13 patients were diagnosed to have septic
arthritis (SA) whereas 19 patients had another diagnosis (5 had
pseudogout, 4 had gout, 4 had seronegative arthropathy, 3 had soft
tissue infection, 1 had osteoarthritis, 1 had haemarthrosis and 1 had no
diagnosis). Out of 13 patients with septic arthritis, 8 were males and
5 were females. Out of 19 patients with another diagnosis, 8 were
males and 11 were females. The mean age of patients with septic
arthritis was 71 (range 43–94 years). The mean age of non-septic
arthritis patients was 66 (range 24–100 years).
Out of 32 patients, 22 patients (8 SA and 14 non SA) had their joint
aspirated prior to antibiotics. 10 patients (5 SA and 5 non SA) failed to
have their joints aspirated prior to antibiotics due to various reasons
(1 needle-phobic, 1 had obvious discharging pus, 2 went straight to
theatre, 1 had cellulitis, 1 was suspected to have some injury and no
reason documented in 4 patients).
Out of the 13 patients with SA, 5 were managed by rheumatologists
and 8 by orthopaedic surgeons. 2 of these 13 patients had prosthetic
joint SA and therefore were managed appropriately by orthopaedic
surgeons. In the 13 patients with SA, appropriate cultures were sent in
all patients (either from the initial joint aspiration or from later surgical
drainage), CRP was measured at baseline in all patients, ESR was
measured at baseline in 3 patients and all patients had serial
measurements of CRP and white cell count but not ESR. The initial
antibiotic choice was in keeping with national or local guidelines in 10
out of 13 patients and there was a delay in management in 2 patients
with SA. 1 of these patients was initially thought to have osteoarthritis
and the other was thought to have a joint injury.
Conclusions: This audit has revealed that about a third of patients
presenting with hot swollen joint fail to have a joint aspiration prior to
starting antibiotics. There is still considerable scope for improvement
in our management of hot swollen joints. Doctors working in the
‘frontline’ should be made aware of these guidelines in order to
improve our practice.
Disclosure statement: All authors have declared no conflicts of
interest.
75. PREVALENCE OF EXTRAHEPATIC RHEUMATOLOGICAL
MANIFESTATIONS IN EGYPTIAN PATIENTS WITH CHRONIC
HEPATITIS C VIRUS INFECTION
Reem H. Abdellatif mohammed1, Hesham I. Elmakhzangy2,
Gamal Esmat2, Amira Gamal3, Fatma Mekky3, Nabil M. Ibrahim4 and
Mohammed A. Elhamid5
1Rheumatology and Rehabilitation, Faculty of Medicine, Cairo
University Hospitals, Cairo, Egypt; 2Tropical Medicine Department,
Faculty of Medicine, Cairo University Hospitals, Cairo, Egypt;
3Department of Community, Enviromental and Occupational
Medicine, Faculty of Medicine, Ein Shams University Hospitals,
Cairo, Egypt; 4Dermatology, National Hepatology and Tropical
Medicine Institute, Cairo University Hospitals, Cairo, Egypt; 5Clinical
Pathology, National Hepatology and Tropical Medicine Institute,
Cairo, Egypt
Background: Chronic HCV viraemia has been known to provoke a
variety of autoimmune-like diseases referred to as extrahepatic
manifestations of chronic HCV infection. Egypt has an exceptionally
high prevalence of HCV infection, estimated to be between 10 and
15% of its 70 million population. The study aimed at evaluation of the
prevalence of extrahepatic rheumatological manifestations of chronic
HCV infection in Egyptian patients and its different clinical presenta-
tions in a way to illustrate the spectrum of these presentation in the
study group.
Methods: All chronic HCV patients attending the outpatient clinic of
the National Hepatology and Tropical Medicine Research Institute
(NHTMRI) through a period of 1 year were interviewed and subjected
to a questionnaire to screen those having rheumatological complaints
then referred to the rheumatologist for evaluation. Laboratory
investigations included complete blood picture, serum transaminases,
serum bilirubin, total proteins, serum albumin, serum urea and
creatinine, complete urinalysis, oral glucose tolerance test.
Serological assay included cryoglobulin profile, rheumatoid factor,
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antinuclear antibody, HCV-PCR. Patients with decompensated liver
disease, on interferon therapy, having end-stage renal disease or
coexisting viral infection like hepatitis B surface antibody positive
patients or human immunodeficiency virus antibodies were all
excluded from the research.
Results: Three hundred and six patients having chronic HCV infection
were interviewed in this research. The diagnosis of HCV induced
rheumatological complaints was done after excluding coexisting
autoimmune diseases (based on American College of Rheumatology
Criteria for the diagnosis or exclusion of autoimmune diseases), non-
inflammatory causes as well as psychological problems. Fifty patients
(16.39%), out of 306 patients [28 males (56%), 22 females (44%) with a
mean age of 45.4 8.7 years] to have clinically significant rheumato-
logical complaints that couldn’t be attributed to another coexisting
disease other than HCV viraemia. The overall estimated prevalence of
autoimmune rheumatological manifestations in the current research
was 16.39%, chronic fatigue syndrome 9.5%, Sicca symptoms 8.8%
(xerostomia 4.9%, xerostomia and xerophthalmia 3.9%), arthralgia
6.5%, fibromyalgia 1.9%, myalgia 1.3%, arthritis 0.7%, cryo-
globulinaemic vasculitis 0.7%, autoimmune haemolytic anaemia
0.7%, thrombocytopaenia 0.7%. Xerophthalmia was significantly
present in male population (P¼ 0.04), whereas fibromyalgia, cryo-
globulinaemic vasculitis, arthritis and autoimmune haemolytic anaemia
were significantly present in female population in the study (P<0.05).
There was no significant correlation between the reported manifesta-
tions and liver function tests, HCV-PCR, or antibody profile.
Conclusions: The estimated prevalence of extrahepatic manifestaions
among Egyptian patients with HCV is 16.39%.
Disclosure statement: All authors have declared no conflicts of
interest.
76. CHRONIC PAIN IN HEPATITIS PATIENTS PRE AND POST
PEG-INTERFERON TREATMENT
Camille Lallemant1, Matthew Greenwood1, Jane Muir2,
Majella Keller1, Jerry Tibble1, Richard Whale2 and Inam Haq2
1Rheumatology, Brighton and Sussex University Hospitals, Brighton,
UK; 2Brighton and Sussex Medical School, Brighton, UK
Background: It is estimated that 3% of the world’s population is
infected by the hepatitis C virus (HCV). The rheumatological
manifestations associated with HCV include vasculitis, arthralgia,
arthritis, myalgia, fatigue and Sicca syndrome. These carry a
significant burden of disease to patients and may be the first
manifestations of HCV infection before they show any hepatic
symptoms. Pegylated-interferon is the most effective and widely
prescribed treatment to date. We investigated whether therapy
modifies the course of the rheumatological manifestations in patients
infected with HCV over time.
Methods: All patients attending HCV Clinics at the Royal Sussex
County Hospital, Brighton were invited to complete a standardized
questionnaire assessing their musculoskeletal symptoms including
pain intensity, questions from the well validated Manchester Pain
Questionnaire, visual analogue scales and questions to determine
clinical classification of Sicca syndrome derived from the Vitali criteria.
This self-administered questionnaire was done at baseline, prior to
treatment initiation and at 6 months post end of treatment.
Results: A total of 178 hepatitis C infected patients were recruited,
117 of whom initiated treatment with pegylated-interferon. Of these
117 patients, 48 were followed-up for 6 months following end of
treatment. Of these patients, 54% are men and 77% are white British.
Their mean age is 45 years with a range from 20 to 66 years. At
baseline, 19% of patients fulfil the Manchester pain criteria. 19% have
experienced swelling of one or more joints and 34% stiffness. 19%
have Sicca symptoms. The mean pain intensity score is 3.95 with 40%
of patients experiencing a pain score above 5. At 6-months post end of
treatment, 10% of patients fulfill the Manchester pain criteria. Although
lower, this percentage is not significantly different from baseline
(P¼0.25). The percentage of patients experiencing swelling of one or
more joints (15%), stiffness (34%) or Sicca symptoms (21%) is not
significantly different from baseline. However, the percentage of
patients experiencing a pain score above 5 (17%) and the mean
pain intensity (2.85) are significantly lower at 6-months post-treatment
compared with baseline (P¼ 0.02 and 0.05, respectively).
Conclusions: This study has shown that HCV positive patients report
a much higher incidence of musculoskeletal pain than that in the
general population in which chronic widespread pain in reported in
about 5% of the population. There is no significant reduction in
prevalence of pain or Sicca symptoms after treatment, although there
was a clear reduction in reported pain intensity at 6 months,
suggesting a role for the virus in the aetiology of musculoskeletal
pain in this patient group. The effect of peg-interferon on reducing pain
in HCV infected patients needs to be confirmed on a larger population.
Long-term follow-up is underway to assess its sustainability.
Disclosure statement: All authors have declared no conflicts of
interest.
77. DISTORTING PROPRIOCEPTION IN PATIENTS WITH
RHEUMATIC DISEASES EXACERBATES SENSORY
DISTURBANCES: FURTHER EVIDENCE FOR CENTRAL PAIN
MECHANISMS
Helen Cohen1,2, Nigel Harris2 and Candy McCabe1,2
1Royal National Hospital for Rheumatic Diseases, Bath, UK;
2University of Bath, Bath, UK
Background: Discordance between motor intention and sensory
perception can generate pain and sensory disturbances in healthy
individuals. Evidence of cortical sensory reorganization exists in many
chronic pain states including complex regional pain syndrome (CRPS)
and fibromyalgia. It has been hypothesized that such neuroplastic
changes render the individual more vulnerable to sensory motor
discordance. This has been demonstrated in fibromyalgia patients. We
hypothesized that similar central pain mechanisms operate across a
spectrum of other rheumatic diseases including osteoarthritis (OA),
rheumatoid arthritis (RA) and CRPS.
Methods: 51 CRPS, 40 OA, 40 RA and 40 healthy controls performed
congruent / incongruent, bilateral upper limb movements for up to
1 min as tolerated while viewing a mirror /whiteboard that created
varied degrees of sensory/motor conflict in four discrete stages. 22
lower limb CRPS patients used their lower limbs. Participants’
descriptions of altered sensations were recorded at each stage of
the protocol. Subjects were assigned to the following vulnerability
classification according to how many of the four stages generated
sensory disturbances (SeD): high¼SeD all stages; moderate¼
SeD3 mirror  3 whiteboard (WB) stages; mild¼SeD2 mirror 
2 WB stages; minimal¼SeD 1 mirror  1 WB stage; nil¼no SeD.
Results: 92% CRPS, 90% OA, 67% RA patients and 60% healthy
controls reported sensory disturbances at some stage in the protocol.
See Table for breakdown of data in terms of vulnerability. Common
descriptions included heaviness, tingling, dizziness, nausea and
perceived loss or gain of a limb. 94% CRPS, 55% OA, 52% RA and
12% of healthy controls reported new pain or exacerbation of existing
pain.
Conclusions: Sensory motor conflict can exacerbate and generate
new somaesthetic sensations and pain in a range of rheumatology
conditions greater than those in healthy controls. This provides further
evidence of central pain mechanisms operating across a spectrum of
rheumatic diseases. Cortical reorganization is already known to exist in
CRPS and contribute to symptoms but this data suggest that in those
conditions where pain was thought to be more peripherally driven (OA,
RA), central mechanisms may play a larger role than previously
considered.
Vulnerability High Moderate Mild Minimal Nil
CRPS 16 18 10 3 4
OA 8 14 11 2 4
RA 2 12 8 5 13
HC 0 7 13 4 16
Figures refer to numbers of subjects. CRPS: complex regional pain syndrome,
OA: osteoarthritis, RA: rheumatoid arthritis, HC: healthy controls.
Disclosure statement: All authors have declared no conflicts of
interest.
78. SARCOPAENIA IS HIGHLY PREVALENT IN THE VERY
ELDERLY AND PREDICTS MORTALITY IN MALES
Michael Cocker1, Roger Francis2, Marco Narici3 and Fraser Birrell4,1
1Newcastle University, Newcastle Upon Tyne, UK; 2Newcastle
Hospitals NHS Foundation Trust, Newcastle Upon Tyne, UK;
3Manchester Metropolitan University, Manchester, UK; 4Northumbria
Healthcare NHS Foundation Trust, Newcastle Upon Tyne, UK
Background: Sarcopaenia is the age-associated loss of skeletal
muscle mass that can lead to frailty, disability and a loss of
independence. The epidemiology of sarcopaenia in those over
85 years is poorly understood. Dual-energy X-ray absorptiometry
(DXA) has been shown to agree with other methods of studying
skeletal muscle mass in patients including MRI and CT. We estimated
the prevalence of sarcopaenia in those over 85 and test associations
with osteoporosis and osteoarthritis and prediction of mortality.
Methods: 167 subjects aged  85 years from one general practice in
Northumberland, UK, were invited to participate. Participants had
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whole body, hip and spine bone mineral density and lateral vertebral
analysis using DXA (iDXA, GE Lunar). Knee and hip radiographs were
scored [Kellgren and Lawrence atlas (KandL)] by a single observer with
established reliability. Sarcopaenia was defined as the lean appendi-
cular mass divided by the subjects height squared  2 S.D. below the
mean for a young and healthy reference population. Vital status of
subjects was ascertained 3 years after initial assessment. Findings
were examined in univariate analysis using 2x2 tables and expressed
as odds ratios with 95% CI and Fisher exact test P values.
Results: Study sample: 29 women and 17 men (median age 87 years
at baseline, interquartile range 4). 59% of men (95% CI 36–82%) were
sarcopaenic, compared with 48% of women (95% CI 30–66%). In
regression analysis, age and weight accounted for 59% of the variance
(P<0.001). 8 subjects (17%) had died at 3-year follow up.
Osteoporosis (classified as T score -2.5) was inversely associated
with sarcopaenia (odds ratio (OR)¼0.89, 95% CI 0.24–3.32). There
was an inverse dose response relationship between sarcopaenia and
vertebral deformity: mild (OR¼0.86, 95% CI 0.27–2.75), moderate
(OR¼0.71, 95% CI 0.22–2.29) and severe (Peto OR¼0.12, 95% CI
0.00–6.25). Small sample size limited the power of this analysis.
Sarcopaenia was associated with a 3.5-fold increased risk of mortality
in men (relative risk (RR)¼3.50, 95% CI 0.51–23.82, P¼0.143). No
association was seen in women (RR¼1.07, 95% CI 0.07–15.54,
P¼0.517). There was no consistent relationship between osteo-
arthritis KandL grade and either sarcopaenia or mortality.
Conclusions: This study has shown that sarcopaenia is more
common than the previous estimate that >40% of those over
80 years old would be classed as sarcopaenic: a significant difference
despite the small sample. The observation that DXA derived
sarcopenia in the very elderly increases the risk of mortality agrees
with grip-strength data in younger subjects and the concept that loss of
>40% muscle mass is a serious health hazard. The gender differences
may be related to the low female mortality in this group: 2/29 women
died compared with 6/17 men. The inverse association between
osteoporosis and sarcopaenia is counterintuitive, as bone and muscle
loss might be expected to be associated. Further work is warranted
to explore the mechanisms responsible for this intriguing finding.
Disclosure statement: F.B., Roche - Unrestricted research grant,
Servier - Unrestricted research grant, GE Lunar iDXA scanner. All other
authors have declared no conflicts of interest.
79. DOES THE DEGREE OF CORTICAL REORGANIZATION
DETERMINE DIFFERENT CLINICAL PHENOTYPES IN
COMPLEX REGIONAL PAIN SYNDROME (CRPS)? A
SENSORIMOTOR STUDY
Helen Cohen1,2, Nigel Harris2, G. Van Velsen1 and Candy McCabe1,2
1Royal National Hospital for Rheumatic Diseases, Bath, UK;
2University of Bath, Bath, UK
Background: Changes in cortical sensorimotor representation have
been documented in CRPS and other chronic pain conditions. It has
been postulated that this may generate incongruent sensorimotor
feedback. A hypothetical right cortical centre for monitoring incon-
gruence of sensation may generate pain and other sensory dis-
turbances when activated. Extent of mechanical hyperalgesia in CRPS
has been correlated to extent of cortical reorganization. We hypothe-
sized that CRPS patients with high vulnerability to sensory motor
discrepancy would have a greater degree of cortical reorganization
exhibited clinically by a larger area and higher intensity of allodynia.
Methods: 41 CRPS patients had quantitative sensory testing using
standard Semmes-Weistein filaments to assess whole body tactile
thresholds and extent of allodynia. The tactile sensory threshold
producing allodynia was recorded. All subjects performed congruent /
incongruent, bilateral upper limb movements for up to 1 min as
tolerated while viewing a mirror /whiteboard that created varied
degrees of sensory/motor conflict in four discrete stages. 22 lower
limb CRPS patients used their lower limbs. Participants’ descriptions
of altered sensations were recorded at each stage of the protocol.
Subjects were assigned to the following vulnerability classification
according to how many of the four stages generated sensory
disturbances (SeD): high¼SeD all stages; moderate¼SeD 3 mirror
 3 whiteboard (WB) stages; mild¼SeD2 mirror  2 WB stages;
minimal¼SeD 1 mirror  1 WB stage; nil¼no SeD.
Results: Only one CRPS patient had no allodynia. Subjects with high
vulnerability (n¼12) to sensorimotor conflict had more extensive
allodynia [mean 21% of body surface area (BSA)] compared with
moderate (n¼ 17) (mean 9% BSA), mild (n¼8) (mean 10% BSA) and
minimal (n¼3) (mean 4% BSA) groups. Comparing the high vulner-
ability group to the other groups (moderate, mild, minimal) combined:
67% had lowered tactile sensory thresholds on the affected limb
compared with 41% in the combined group; 50% had allodynia to the
normally undetectable 0.008 g filament compared with 14% of the
combined group; mean disease duration was 7 years in the high group
compared with 4 years in the others.
Conclusions: CRPS patients with high vulnerability to sensory motor
discrepancy have more extensive and severe allodynia, with a longer
disease duration compared with less vulnerable groups. The data
supports the hypothesis that greater cortical reorganization is present
in the high vulnerability group, which may contribute to the clinical
phenotype. This may allow a more structured approach to the
phenotyping and treatment of CRPS.
Disclosure statement: All authors have declared no conflicts of
interest.
80. IMPROVED HEALTH-RELATED QUALITY OF LIFE IN
PATIENTS WITH CRYOPYRIN-ASSOCIATED PERIODIC FEVER
SYNDROME (CAPS) AFTER TREATMENT WITH
CANAKINUMAB-A FULLY HUMAN ANTI-IL-1 b MONOCLONAL
ANTIBODY
H. J. Lachmann1, I. Kone-Paut2, J. B. Kuemmerle-Deschner3,
K. Leslie4, E. Hachulla5, P. Quartier6, A. Ferreira7, N. Patel8,
K. Lheritier7, R. Preiss8 and P. Hawkins1
1National Amyloidosis Centre, UCL Medical School, London, UK;
2Hopital, Kremlin Bicetre, Le Kremlin Bicetre, France;
3Pediatric Rheumatology, Universita¨tsklinik, Tu¨bingen, Germany;
4UCSF, School of Medicine, San Francisco, CA, USA; 5Service de
Medicine Interne, Hopital Claude Huriez, Lille Cedex, France;
6Unite´ d’Immunologie, Hopital Necker Enfants Malades, Paris,
France; 7Novartis Pharma AG, Basel, Switzerland;
8Novartis Pharmaceutical Corporation, East Hanover, NJ, USA
Background: The direct impact of CAPS on patients’ well-being is
often underestimated due to limited data on patients’ perception of the
disease. In the 48-week pivotal Phase III study with canakinumab in
CAPS, health reported quality of life (HRQoL) was assessed at baseline
and during treatment using patient reported outcomes that evaluate
the direct impact of the disease on patients’ well-being and
improvements following canakinumab treatment.
Methods: In this three-part study, patients received canakinumab
150 mg s.c. or 2 mg/kg s.c. (body weight  40 kg) every 8 weeks.
HRQoL was assessed in adults using the following domains: general
mental and physical health (SF-36), fatigue (FACIT-Fatigue) and
functional disability (HAQ-DI).
Results: Lower baseline scores for general mental and physical health
(SF-36) and fatigue (FACIT-Fatigue) than the general population
demonstrate that CAPS has significant impact on patients’ well-
being (Table). After the first canakinumab dose, SF-36 and FACIT-
Fatigue scores improved to the levels expected in the general
population. An improvement in functional disability was observed as
shown by HAQ-DI scores. At the end of this 1-year study (48-weeks),
HRQoL scores were comparable to those observed following the first
injection and suggest that patients’ well-being has improved to levels
seen in the general population without chronic disease.
Conclusions: CAPS has a significant impact in patients’ well-being
due to the physical effects of systemic inflammation mediated by
direct neurotrophic effects of IL-1b leading to the deleterious effects
on patients’ physical and mental health. Canakinumab every 8 weeks
provides improvement in quality of life, to that of the general
population, across a variety of standardized measurement tools
addressing physical and emotional well-being as well as fatigue.
Comparison of HRQoL scores of CAPS patients treated with canakinumab
Component General US
population,
mean (S.D.)
n Baseline,
mean (S.D.)
End of study
(48 weeks),
mean (S.D.)
Change
from
baseline,
mean (S.D.)
SF-36 (0-100)
Physical component 50.0 (10.0)a 22 40.4 (9.3) 48.5 (12.6) 8.2 (9.4)
Mental component 50.0 (10.0)a 22 42.6 (12.4) 48.9 (12.4) 6.3 (12.4)
- Physical functioning 84.2 (23.3)a 23 74.1 (28.8) 82.6 (25.7) 8.5 (23.0)
- Role-physical 80.9 (34.0)a 26 50.0 (48.0) 76.0 (40.3) 26.0 (47.7)
- Bodily pain 75.2 (23.7)a 25 48.0 (23.0) 76.5 (30.2) 28.6 (31.8)
- General health 71.9 (20.3)a 25 46.4 (17.2) 60.8 (23.2) 14.4 (17.6)
- Vitality 60.9 (20.9)a 26 42.5 (22.2) 60.0 (28.5) 17.5 (30.5)
- Social functioning 83.3 (22.7)a 25 67.5 (29.1) 77.5 (33.5) 10.0 (36.3)
- Role-emotional 81.3 (33.0)a 25 58.7 (46.4) 73.3 (41.9) 14.7 (46.2)
- Mental health 74.7 (18.1)a 26 64.5 (21.5) 74.2 (21.7) 9.7 (20.5)
FACIT-fatigue 43.6 (9.4)b 26 27.4 (13.0) 39.5 (14.7) 12.2 (16.9)
HAQ-DI (0-3) Not available 26 0.41 (0.6) 0.27 (0.5) -0.14 (0.4)
n¼ number of patients having both baseline and end of study values. aAdapted
from Ware J, et al. SF-36 Physical and Mental Health Summary Scales: A user’s
manual. Boston, MA: The Health Institute. 1994 bAdapted from Cella D, et al.
Cancer 2002;94:528-38.
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81. MANAGEMENT OF THROMBOSIS IN 62 PATIENTS WITH
BEHC¸ET’S SYNDROME OVER 15 YEARS
Puja Mehta1, Mike A. Laffan2 and Dorian O. Haskard1
1Department of Rheumatology, Imperial College Healthcare NHS
Trust, London, UK; 2Department of Haematology, Imperial College
Healthcare NHS Trust, London, UK
Background: Behc¸et’s syndrome (BS) is a rare, heterogeneous
inflammatory disease characterized by recurrent orogenital ulceration,
uveitis and multi-organ involvement. Vascular involvement occurs in
10–30% of patients and is more commonly observed in males.
Superficial or deep venous thrombosis (DVT) is the most frequent
manifestation of vascular Behc¸et’s, although pulmonary embolism is
rare. Aneurysms are the most common arterial feature and may confer
serious bleeding risks. Venous thrombosis is largely due to vessel wall
inflammation. Hypercoagulability may be partially culpable, although
thrombophilic factor abnormalities do not correlate with clinical
thromboses. A recent small study compared the use of immune
suppression and anticoagulation to treat thrombosis in BS. However,
there have been no comprehensive studies to determine optimal
treatment for thrombosis and therefore a consensus has not been
reached. We report a review of thrombosis in patients attending our
tertiary referral Behc¸et’s clinic and propose management strategies for
investigation, treatment and prophylaxis.
Methods: Review of our prospectively maintained database of 657
patients seen between 1994-2009 identified 64 patients (10%) with
vascular complications. 62 case notes were available for review. All
patients fulfilled ISG diagnostic criteria. Patients with isolated super-
ficial thrombophlebitis were excluded.
Results: The majority of patients in our vascular cohort were male
(62%) and had experienced at least one thrombosis prior to being
referred to our centre (92%). DVTs were the most frequent vascular
event (71% of patients) and thrombosis was the event that led to a
diagnosis of Behc¸et’s in 63% of cases. 53% of patients had more than
one thrombosis. Half of all patients had a thrombophilia screen and 13%
of genetic thrombophilia tests were positive. All patients had imaging
specific to the site of thrombosis. One third had clinical indication for
additional pulmonary imaging. 35% of patients imaged had positive
findings, such as aneurysms. Most patients were anticoagulated (89%),
with plans for the duration of warfarin treatment documented in 42%
of cases. The median duration of anticoagulation was 6.2 years
and 40% of patients remained on life-long warfarin.
Conclusions: Our findings demonstrate that management of throm-
bosis in BS is variable. We suggest targeting underlying vascular
inflammation as a priority using steroids and immunosuppressive
agents, such as azathioprine. Anti-coagulation of in-situ thrombosis
should be viewed as an adjunct. Duration of anti-coagulation should
be dependent on disease activity and presence of thrombophilic traits.
All patients should have thrombophilia tests and screening for
aneurysms should be considered, especially in young males.
Disclosure statement: All authors have declared no conflicts of
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Background: There are only scattered case reports of marked
neutropenia with etanercept; however, the rechallenge with etanercept
is not well described
Methods: We would like to report 4 patients who developed neutro-
penia with etanercept use and they were subsequently rechallenged
Results: A 64 year old woman with erosive RA was commenced on
etanercept 50 mg weekly in August 2008. Her baseline white cell count
(WCC) on methotrexate was 4.9 x 109/l and neutrophil cell count (NCC)
of 2.65 x 109/l [NCC normal range 1.8-8 x109/l]. However, after
2 weeks of starting etanercept, her WCC dropped to 3.6 x 109/l, with
NCC of 1.99 x109/l, which dropped further to 1.37 x109/l. Because of
her positive clinical response, we decided to continue with etanercept
and to monitor her full blood count every 2 weeks. So far, her cell
counts have remained stable (NCC¼ 1.8–2.0 x 109/l).
A 36-year old man was diagnosed with ankylosing spondylitis in
2009. The etanercept was commenced in July 2009 and he had
a dramatic clinical response. His WCC pre etanercept use was
4.3 109/l with NCC of 2.72 109/l; however, with etanercept, her
NCC dropped to 1.41109/l and remains stable so far. He remains on
etanercept monotherapy and being closely monitored.
A 65-year old man with seropositive RA was commenced on
etanercept in February 2004 and he reported marked improvement of
his symptoms. His WCC before commencing on etanercept was 5.5
x109/l with NCC of 3.54 x109/l. A very gradual reduction in his NCC
was observed; these dropped to 1.77 x 109/l in May 2004. He
developed erysipelas and respiratory tract infection and etanercept
was put on hold. His WCC gradually rose to baseline figures and he
was re-challenged with etanercept. His NCC dropped but remained
stable around 2.1-2.6 x109/l. However, in January 2008 his WCC
dropped significantly to 2.9 x109/l with NCC of 1.17 x 109/l and these
responded to etanercept withdrawal. It was then decided to
commence him on adalimumab. His WCC dropped again from 4.7 to
3.7 x109/l with NCC from 2.95 to 2.06 x109/l and we are monitoring his
monthly blood tests.
A 71-year old lady with seropositive RA was commenced on
etanercept in November 2007. Her baseline NCC was 5.53 x109/l.
After two injections of etanercept, a gradual decline in her NCC was
observed; this gradually got worse in May 2008 when the NCC fell to
1.06 x109/l. She was taken off etanercept and her NCC rapidly
improved to her baseline figures. Etanercept was re-introduced in July
2008. Her NCC has dropped modestly, but they have remained quite
stable since (neutrophil count 1.7–2.0 x109/l).
Conclusions: We describe these cases, which have changed the
clinical practice in our unit; now, all patients using TNF blockers get
monthly blood tests. Second, we have re-challenged these patients
without any clinical complications, revealing that patients with mild to
moderate neutropenia can be safely exposed to TNF blockers as long
as they are monitored with regular cell count checks.
Disclosure statement: All authors have declared no conflicts of
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84. A COMPARISON OF PATIENTS REFERRED AFTER
FRACTURES OF THE FOREARM AND FRACTURES OF THE
SPINE AND HIP
Marwan Bukhari1,2, Cathi Greenbank1, Bronwen Evans1,
Nicola Goodson2 and John Halsey1
1Rheumatology, Royal Lancaster Infirmary, Lancaster, UK; 2Clinical
Sciences, Univeristy of Liverpool, Liverpool, UK
Background: Recent guidance has emphasized the importance of
bone mineral density (BMD) of the hip and other clinical predictors to
be important in predicting fractures. We aimed to see if this differs
between different fracture types. Importantly, we wished to see if
patients referred after a Colles fractures where different from those
referred after a fracture hip and spine. In a previous analysis, we
identified that spine and hip fractures had different predictors. Our aim
was to determine whether predictors of fracture are different in
patients referred after a Colles fracture than populations referred after
sustaining hip or spine fractures.
Methods: The Morecambe bay osteoporosis database of patients
referred between June 2004 and September 2007 was queried for
patients referred after a spine, hip or forearm fracture. These two
cohorts were subsequently compared with the Colles fracture group
for risk factors for osteoporosis using chi squared test for binary
predictors and t student’s T test for continous predictors.
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